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Abstract Neuroimaging plays an important role in etio-
logic research on neurological diseases in the elderly. The
Rotterdam Scan Study was initiated as part of the ongoing
Rotterdam Study with the aim to unravel causes of neu-
rological disease by performing neuroimaging in a popu-
lation-based longitudinal setting. In 1995 and 1999 random
subsets of the Rotterdam Study underwent neuroimaging,
whereas from 2005 onwards MRI has been implemented
into the core protocol of the Rotterdam Study. In this paper,
we discuss the background and rationale of the Rotterdam
Scan Study. We also describe the imaging protocol and
post-processing techniques, and highlight the main ﬁndings
to date. Finally, we make recommendations for future
research, which will also be the main focus of investigation
in the Rotterdam Scan Study.
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Introduction
Neurologic diseases in the elderly, such as dementia and
stroke, will pose an ever increasing burden on societies
over the next couple of decades [1–4]. However, effective
therapeutic or preventive strategies are lacking. In order to
develop such strategies, knowledge on the etiology of these
diseases is essential. A feature of neurodegenerative dis-
eases is that morphologic brain pathology may be already
present years before clinical onset and can be visualized
using magnetic resonance imaging [5–10].
Realizing this potential beneﬁt, already in the 1990s
various population-based studies implemented neuroimag-
ingtostudythepreclinicalbrainchangesthatultimatelylead
to or may indicate an increased risk of developing clinically
manifest diseases, such as dementia and stroke [7, 11–19].
However,moststudies implemented neuroimaging inonlya
subset of their population leading to limited sample sizes.
More importantly, over the course of the last two decades
MR imaging has undergone a dramatic improvement in
hardware and software leading to higher ﬁeld strengths,
higherresolution,shorterscanningtimes,andmoresensitive
sequences. Furthermore, digital imaging techniques have
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increasing through-put of image processing for better visu-
alization and quantiﬁcation of imaging ﬁndings. Taken
together, these developments now allow for performing
neuroimaging in larger sample sizes and using state-of-the-
art imaging and processing techniques. In turn, this has
openedthewayformoreindepthandthoroughinvestigation
of (more subtle) brain changes that can lead to neurological
diseases.
It was in this light, that in 1995 the Rotterdam Scan
Study was initiated to investigate risk factors and risk
indicators of neurological diseases in the elderly using MR
imaging to visualize the underlying brain changes and
brain pathology. In 1995 and 1999, random subsets of the
Rotterdam Study underwent neuroimaging off site in
clinical scanners. From 2005 onwards, the Rotterdam Scan
Study has been embedded within the core protocol of the
Rotterdam Study. This was possible due to installation of a
dedicate research scanner on site.
The purpose of this paper is to give a general outline of
the study population, scanning protocol, image post-pro-
cessing and to discuss the main ﬁndings of the Rotterdam
Scan Study, with the main focus on the period from 2005 to
2011.
Design and study population
The source population of the Rotterdam Scan Study orig-
inates from the Rotterdam Study [20–23], which is a
population-based study in the Netherlands and aims to
investigate causes and determinants of chronic diseases in
the elderly. The Rotterdam Study (RS I) was initiated in
1990 with 7,983 participants aged 55 years and over, who
were interviewed and underwent physical exam at baseline
and during follow-up visits every 3–4 years. In 2000 the
cohort was expanded by 3,011 persons (RS II), who were
aged 55 and over at that time. In 2006 the cohort was
further expanded by 3,932 persons aged 45 years and over
(RS III). The whole cohort undergoes re-examinations
every 3–4 years. The total Rotterdam Study population
encompasses 14,926 persons.
Figure 1 shows an overview of the various Rotterdam
Study cohorts, the time of their (re-)examination visits, and
the implementation of MRI-scanning in the core protocol
of the Rotterdam Study in 2005. Initially, we invited ran-
dom persons from the second visit of RS II to undergo
MRI. Subsequently, we have scanned all eligible and
consenting participants from the ﬁrst visit of RS III and
ﬁfth visit of RS I. Currently, persons from the third visit of
RS II are undergoing scanning. For 2012, participants
from RS III are scheduled to be re-invited. Because the
throughput of performing MR imaging has been higher
than that of the Rotterdam Study (56 MRI slots per week
versus 36 slots for regular study center visits), we were able
to invite additional subsets for re-scanning. As such, we re-
invited participants from RS I in 2006, RS II in 2008, and
RS III in 2010 outside their regular visits for the Rotterdam
Study. As a result, some of the participants are already
undergoing their third MRI-exam.
Of all persons taking part in the Rotterdam Study, those
who are demented or with MRI contra-indications are
considered not eligible for the Rotterdam Scan Study.
Furthermore, persons suffering from claustrophobia are
also not considered further. Therefore, as of January 2011,
a total of 5,886 brain MR-scans have been obtained on the
research scanner. This includes multiple scans from the
same person.
Scan protocol
In 2005, a 1.5T MRI unit (General Electric Healthcare,
Milwaukee, USA, software version 119) dedicated to the
research project was installed in the Rotterdam Study
research center. Besides the possibility of high throughput
image acquisition, this enabled us to maintain acquisition
parameters unchanged by excluding software or hardware
upgrades in order to ensure data stability and comparability
over time. The MRI unit was ﬁtted with a dedicated
8-channelheadcoil(bestcoilconﬁgurationavailableattime
of installation) and the possibility for parallel imaging using
the array spatial sensitivity encoding technique (ASSET).
Maximum total examination time (from arrival of one
participant in the MRI suite until the next) was set at
45 min, in order to accommodate the MRI acquisition into
the generic workﬂow of the Rotterdam Study. We therefore
designed a 30 min brain imaging protocol that balanced the
restrictions of time, costs and inconvenience for the par-
ticipants with the relevance and quality of the acquired
imaging data. To ensure participant compliance and
reproducible image quality (reduce motion artefacts) an
acquisition limit of 6 min per sequence was chosen.
To facilitate easier applicability of the current MRI
protocol by radiology technicians, we chose to use the
standard brain imaging package delivered by the system
manufacturer instead of custom developed sequences.
The MRI sequences were chosen based on the primary
variables of interest, i.e.:
1. quantitative measures of brain tissue volumes and
volumes of various neurostructures (e.g. hippocampus)
2. quantitative assessment of white matter lesions,
3. qualitative assessment of brain infarcts (lacunar and
cortical) and microbleeds,
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1234. quantitative assessment of white matter microstruc-
tural integrity and connectivity,
5. quantitative assessment of total cerebral blood ﬂow.
In designing the protocol, we tried to meet both the time
constraint and the contrast and resolution requirements.
Where possible, we preferred 3D over 2D sequences
because of higher signal-to-noise ratio (SNR), enabling the
acquisition of smaller voxel sizes. Yet, acquisition time,
sensitivity to motion and blurring artefacts did not allow
3D acquisition in all sequences. For each sequence, we
adjusted the imaging parameters during optimization pro-
cedures to obtain a speciﬁc target resolution with adequate
SNR (C25) for tissues in the center of the brain while scan
time was limited to 6 min for each sequence.
The resulting protocol is presented in the Table 1 with
all the relevant imaging parameters and the execution
order listed. The protocol starts with a three-plane local-
izer, executed with the shimming option enabled. For
subsequent sequences shimming is turned off to accelerate
receiver adjustments. Morphological imaging is performed
with T1-weighted (T1w), proton density-weighted (PDw)
and ﬂuid-attenuated inversion recovery (FLAIR) sequen-
ces. The combination of different MR contrasts provided
by these sequences can be used for automated brain tissue
and white matter lesion segmentation (see section on
processing). For this purpose, the T1w scan is acquired in
3D at high in-plane resolution and with thin slices (voxel
size\1m m
3). A 3D T2*-weighted gradient-recalled echo
(GRE) scan is used to image cerebral microbleeds. For
this sequence a TE[30 ms was selected to obtain
stronger T2*-weighting. For registration purposes, the
same slice thickness with a lower in-plane resolution as
compared to the 3D T1w scan is used. Parallel imaging is
applied for this sequence to stay within the 6 min scan
time limit.
Diffusion tensor imaging (DTI) is used to quantitatively
assess white matter microstructural integrity [24, 25]. For
this 2D DTI scan, we use an echo planar imaging (EPI)
readout with gradients (b = 1,000 s/mm
2) applied in 25
directions [24, 25]. The b = 0 s/mm
2 image is collected
with NEX = 3. The number of gradient directions, i.e. 25,
was chosen to best ﬁt the optimized protocol by Jones et al.
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Fig. 1 Overview of the subcohorts and examination visits of the
Rotterdam Study, and imaging visits of the Rotterdam Scan Study.
Boxes indicate examination visits of the three cohorts of the
Rotterdam Study. Boxes with solid colors indicate visits, during
which MRI imaging was conducted as part of the core protocol.
Examination visits indicated with an ‘X’ indicate extra visits during
which only MRI was performed. The red vertical line indicates the
implementation of MRI on site in the core protocol of the Rotterdam
Study. In 1995 and 1999 (indicated with *) 567 persons underwent
MRI as part of the Rotterdam Scan Study outside the core protocol of
the Rotterdam Study. ‘Total’ indicates the total number of persons
taking part in that Rotterdam Study examination visit. ‘N’ indicates
the number of persons that were eligible (non-demented and no MRI
contra-indications) and invited to take part in the Rotterdam Scan
Study. ‘n’ indicates the number of persons taking part in the
Rotterdam Scan Study
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123[24, 25] whilst remaining within time limits and maximum
number of slices permitted by the scanner. To minimize
geometrical distortions, the number of frequency encoding
points was set to 64 and parallel imaging was applied with
an acceleration factor of 2, with an imaging matrix of
64 9 96 and providing a voxel size of 3.3 9 2.2 9
3.5 mm
3.
An ungated 2D GRE phase contrast ﬂow measurement is
applied for assessment of total cerebral blood ﬂow [26],
which has shown to be fast and accurate [26]. A 2D thick
slab projection phase contrast angiographic localizer
(60 mm thick, velocity encoding (VENC) = 60 cm/sec) is
positioned sagittally to determine the location of the carotid
and basilar arteries. Next a thin slice perpendicular to all
three vessels at the level of the precavernous internal carotid
artery is positioned (VENC = 120 cm/s, slice thickness
5 mm, NEX = 8). Flow velocity data can be calculated
from the phase difference images as described before [26].
Figure 2 illustrates an example of all the different
sequences acquired in the ﬁnal protocol. The sequence
acquisition order was chosen in a way to provide adequate
reconstruction speeds and to eliminate delays. The 3D
T2*w GRE scan was the last sequence executed in the
protocol pipeline because of the long reconstruction time
necessary for parallel imaging and the resulting lag time in
scan execution.
For quality check, a daily quality assessment (measuring
transmit gain, center frequency and SNR) is performed by
technicians using a phantom. In addition, weekly mea-
surements of echo-planar stability, isocenter reliability and
accuracy of absolute scaling along the cardinal axes (x, y,
z) are performed. Regular scanner maintenance is per-
formed by the manufacturer and results are ﬁled in a log.
Furthermore, interscan reproducibility measurements
have been performed by re-inviting study participants
(n = 20–30) within on average 2 weeks after initial exam-
inationforrepeatMRI.Bothforbraintissuesegmentationas
well as for diffusion tensor connectivity analysis, interscan
reproducibility has been shown to be very good [27].
Image processing
Within the context of the Rotterdam Scan Study, a stan-
dardized and validated image analysis workﬂow is being
developed to enable the objective, accurate, and repro-
ducible extraction of relevant parameters describing brain
anatomy, possible brain pathologies, and brain connectivity
from multispectral MRI data. Image processing in the
Rotterdam Scan Study has initially been centered around
three main goals: First, owing to the sheer size and com-
plexity of the imaging database being generated, we aim to
automate the tedious task of manual analysis, both
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123qualitative (e.g. use of rating scales, for example for
cortical atrophy) and quantitative (e.g. manual contouring
for volume analyses). Second, our goal is to replace qual-
itative image assessment by quantitative analyses as much
as possible. Third, we aim to limit or avoid altogether inter-
and intraobserver variability. In recent years, image pro-
cessing has been expanded to also allow the extraction of
relevant image-derived parameters that would not be fea-
sible manually or cannot be assessed visually.
In the following paragraphs, we brieﬂy describe the dif-
ferent quantitative image analysis methods that have been
developedand/oremployedwithintheRotterdamScanStudy.
Image pre-processing
Prior to analysis, a number of pre-processing steps are
performed. For multispectral image analysis, the different
scans are spatially registered using rigid registration.
Subsequently, the brain is extracted from the scan. Hereto a
manually segmented brain mask, which excludes a.o. the
cerebellum, eyes and skull, is non-rigidly registered to the
T1-weighted image using Elastix [28].
Finally, scans are corrected for intensity non-uniformity
using the N3 method [29]; non-uniformity correction is
carried out within the brain mask.
Brain tissue segmentation
Automated brain tissue segmentation on MRI has received
considerable attention [11, 30–39]. An important distinction
that can be made is whether methods are supervised (i.e.
they depend on annotated training data), or unsupervised. In
the Rotterdam Scan Study we have used two types of
supervised approaches, both based on k-nearest neighbour
(kNN) segmentation. In kNN segmentation, image voxels
are assigned labels (grey matter (GM), white matter (WM),
Fig. 2 Depiction of the images
acquired using the MRI
protocol. First row: T1-
weighted (a), proton-density-
weighted (b), and ﬂuid
attenuated inversion recovery
(c) images. Second row: T2*-
weighted (d) image, sagittal
scout for the 2D phase contrast
measurement (e), and the
resulting ﬂow image (f). Third
row: example of an image
acquired using diffusion tensor
imaging (g), map of fractional
anisotropy (h), and map of mean
diffusivity (i)
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123cerebrospinal ﬂuid (CSF) or background (BG)) based on the
most similar voxels in the training data. Similarity here
depends on the distance in normalized MR image intensi-
ties. We have both investigated segmentation based on T1w
images,andmultispectralMRIdata(T1wandPDwimages).
The two approaches we have used differ in the way that the
training data are obtained. In the ﬁrst approach manual
segmentations by two observers of six T1w datasets (the
PDw dataset is implicitly segmented after rigid registration
to the T1w datasets), that include labels for GM, WM, CSF,
and BG, were used as training data [30, 40]. In the second
approach the training data were obtained from the scan to be
segmented itself. Hereto, the manually segmented scans are
used as atlases and are non-rigidly transformed to the scan,
creating probability density maps that indicate the likeliness
ofeachvoxeltobelongtoacertaintissuetype.Afterrandom
selection of likely voxels for each class, and a pruning step
to remove outliers, the training samples for WM, GM, CSF
and BG are obtained [40, 41].
Both methods have been extensively evaluated within
the context of the Rotterdam Scan Study, showing good
accuracy and reproducibility [27, 40]. An example of the
automated tissue segmentation is shown in Fig. 3.
Tofacilitatemoreregionalizedanalysisoftotalbrain,WM
and GM volumes, individual lobes have been segmented.
This is achieved by non-rigidly registering a template image
in which the lobes have been manually outlined [42–44].
White matter lesion classiﬁcation
The brain tissue segmentation methods described above
have been complemented with white matter lesion (WML)
segmentation [45]. Hereto, both the brain tissue segmen-
tation, and the FLAIR image is used. In the brain tissue
segmentation, possible WMLs are misclassiﬁed as GM
with a ring of WM voxels. In the FLAIR image the WMLs
are hyperintense. We therefore process the histogram from
the FLAIR image intensities of all voxels that are classiﬁed
as GM, to estimate the mean and standard deviation of true
GM voxels. Subsequently, WML voxels are extracted by
intensity thresholding, where the threshold depends on the
estimated GM distribution. False positives are removed by
excluding voxels which are not sufﬁciently connected to
the white matter. The different parameters (intensity
threshold, and quantitative deﬁnition of not being sufﬁ-
ciently connected) have been optimized on large reference
dataset. The method has been quantitatively evaluated [45]
and has successfully been applied to the whole cohort [46].
Visual inspection of the results indicates that the method is
robust, with approximately only 4% of the scans containing
false positive or false negative WMLs. Figure 4 demon-
strates the automated WML segmentation result.
Brain structure segmentation and shape analysis
Within the Rotterdam Scan Study we have developed a
graph cut framework for neurostructure segmentation [47]
combining atlas registration and statistical models of image
appearance [48]. As the hippocampus is one of the ﬁrst
regions to be affected by Alzheimer’s disease, most work
has focused on developing and optimizing the framework
for this application.
The developed framework requires annotated training
data (atlases), which are used both for atlas registration,
Fig. 3 K-nearest neighbor
based tissue segmentation into
grey matter (red), white matter
(yellow), cerebrospinal ﬂuid
(blue), and background (black)
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123and for training the statistical image appearance models.
Two observers manually outlined the hippocampus in
twenty datasets, following a well-described protocol [49].
The twenty atlases are nonrigidly registered to an image to
be segmented, after which by averaging a spatial proba-
bility map is obtained which indicates the likeliness of a
voxel to belong to the hippocampus. Within the graph cut
framework, this information is complemented by the like-
liness that a voxel is part of the hippocampus based on
intensity information. Hereto voxel intensities are related
to the expected intensity distributions of the hippocampus
and the surrounding tissue. The method has been shown to
improve on existing manual hippocampus segmentation
techniques [48], and has been applied to a number of
studies [50, 51]. An example of hippocampus segmentation
is shown in Fig. 5. The graph cut framework developed for
hippocampus segmentation has additionally been used for
ventricle segmentation [52], and segmentation of the cer-
ebellum [53]. We are working on further extending the
applicability to other neurostructures.
Currently, our focus extends beyond plain volumetry to
incorporating shape-based analysis. Therefore, we have
developed a method to quantify hippocampal shape, and
investigated its potential to predict dementia. Because our
aim is prediction, the most suitable datasets are those
obtained in 1995, which have more than 10 years of clin-
ical follow-up. We compared MRI scans of 47 persons who
were cognitively normal at scan time and developed
dementia during 10-years of follow-up, with 47 age- and
gender-matched controls who remained free of dementia. A
statistical shape model was built from the 94 segmentation
results and was used to predict incident dementia. We
found that the combination of hippocampal volume and
hippocampal shape performed better than when just using
volume [54].
Diffusion tensor imaging: global and tract-based
analysis
DTI enables measurement of the microstructural integrity
of white matter. Within the Rotterdam Scan Study, a
number of image analysis techniques have been employed
and developed for the analysis of DTI data. These include
conventional global and regional analysis of DTI-derived
measures such as Fractional Anisotropy (FA) and Mean
Diffusivity (MD) [55], and tract-based analysis of FA [56].
Global and regional analysis of FA and MD has been
performed using the FSL toolbox [57], and consisted of
Eddy current correction, head motion correction, skull
stripping and tensor model ﬁtting. As discussed below, DTI
data were registered with the other imaging data to study
relations between atrophy, white matter lesions, and DTI-
derived measures.
Tract-based analysis of DTI enables a more localized
comparison of FA and MD between groups. In the Rot-
terdam Scan Study, tract-based analysis has been achieved
using tract-based spatial statistics (TBSS) [58] a technique
Fig. 4 White matter lesion
segmentation (purple), using
both the FLAIR image (left) and
brain tissue segmentation
(Fig. 3) as input
Fig. 5 Hippocampus segmentation, which is used as a basis for both
volumetric and shape analysis
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from a series of images, onto which for each individual the
local maximum FA value is projected. This enables robust
voxelwise statistical analysis of the microstructural integ-
rity of white matter across persons [56]. Statistical analysis
is performed with multiple linear regressions, adjusting for
age, sex and multiple comparisons. In addition, to study
relations between macroscopic white matter changes and
white matter microstructure, DTI data are aligned with the
other MR imaging data.
Diffusion tensor imaging: connectivity analysis
Using deterministic or probabilistic tractography, DTI can
also be used to study structural connectivity of the brain. In
order to compare structural connectivity across persons in
the Rotterdam Scan Study, we developed a novel frame-
work, SAMSCo, which enables construction of weighted
structural brain connectivity networks which can be
effectively analyzed using statistical methods [59, 60]. The
weighted networks are obtained using a minimum cost path
(mcp) method with an anisotropic local cost function based
on the locally estimated diffusion tensor weighted images.
Start and end regions of the mcp were deﬁned by a Free-
Surfer segmentation [61, 62] of subcortical structures and
cortical parcellation. In proof of principle experiments we
showed that the brain connectivity maps contain informa-
tion on age and sex [59, 60]; we hypothesize that it can also
be used for getting valuable insight into normal brain
ageing and disease progression. Using a re-scan on 30
persons, good reproducibility of the connectivity maps was
shown [27].
Visual ratings
Scan quality and incidental ﬁndings
Each MRI scan that is acquired is visually examined within
1 week after acquisition by a research physician in the
Rotterdam Scan Study. During this visual inspection, the
MRI scan is rated for quality and the presence and severity
of motion artefacts or signal inhomogeneity (for example
due to metallic implants) is recorded. Furthermore, each
scan is evaluated by trained research physicians for pres-
ence of incidental ﬁndings, i.e. abnormalities of potential
clinical relevance that were previously unknown, that are
unexpected and that are unrelated to the purpose of the scan
[63, 64]. All potential ﬁndings are recorded in a database
and are in a later stage evaluated by an experienced neu-
roradiologist. The most frequent ﬁndings in the Rotterdam
Scan Study are aneurysms (1.8%) and benign primary
tumors (1.6%) [63]. Referral of participants for further
medical examination occurs in accordance with an expert-
deﬁned protocol [63].
Ischemic small vessel disease on MRI
Infarcts are rated on FLAIR, proton density-weighted, and
T1-weighted sequences. Lacunar infarcts are deﬁned as
focal lesions C3 and\15 mm in size with the same signal
characteristics as CSF on all sequences, and (when located
supratentorially) with a hyperintense rim on the FLAIR
sequence [63]. Lesions C15 mm in size, but otherwise
similar, are rated as subcortical infarcts. Infarcts showing
involvement of cortical gray matter are classiﬁed as cor-
tical infarcts.
Cerebral microbleeds
All 3D T2* GRE scans are reviewed for the presence,
number, and location of cerebral microbleeds. Microbleeds
are deﬁned as focal areas of very low signal intensity on
T2*-weighted imaging that are not accompanied by evident
signal abnormality on other structural sequences [65].
Microbleed location is categorized into one of three loca-
tions: lobar (cortical gray and subcortical or periventricular
white matter), deep (deep gray matter: basal ganglia and
thalamus, and the white matter of the corpus callosum,
internal, external, and extreme capsule), and infratentorial
(brainstem and cerebellum) [65]. Intraobserver and inter-
observer reliabilities for microbleed rating are very good
(j = 0.85–0.87 [66]) and review of the intial ratings by an
experienced neuroradiologist yielded very high accordance
as well [66].
Visual check of automated processing performance
Though post-processing for tissue segmentation and
structure segmentation takes places fully automated and
without user interaction, all end results are visually
checked for performance. For example, small motion
artefacts in the FLAIR sequence that do not necessitate
exclusion of an MRI scan may interfere with white matter
lesion segmentation and cause false positive lesions after
automated segmentation; or brain masking may result in
minimal inclusion of dura or skull. After visual inspection,
manual editing of any errors is needed in less than 10% of
scans, depending on the type of post-processing. Further-
more, less than 1% of scans are excluded based on artefacts
that are only discovered after automated post-processing
(for example motion or susceptibility artefacts in diffusion
tensor images, which are not apparent in the raw unpro-
cessed data).
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Vascular factors and brain pathology
Previous experience with brain MRI in the Rotterdam
Study had learned that markers of small vessel disease such
as white matter lesions and lacunar infarcts are highly
prevalent in the elderly and that these relate to common
cardiovascular risk factors [44, 67–78]. In the MRI scans
obtained from 2005 onwards, we conﬁrmed the frequent
occurrence of WML and infarcts in the elderly and further
extended the prevalence and volume estimates to the
middle aged population [63]. Furthermore, cerebral mi-
crobleeds were added as a new marker of vascular brain
pathology, and their interrelationship with ‘classic’ mark-
ers of small vessel disease was examined (see further
below). In addition to known classic cardiovascular risk
factors, we examined cerebral blood ﬂow as a measure of
brain perfusion and studied its determinants and associa-
tion with cognition and vascular brain disease, as further
described below. In line with this, we investigated the
association between arterial calciﬁcation (measured with
computed tomography), a relatively new marker of ath-
erosclerosis, and subclinical vascular disease and found
arterial calciﬁcation in various vessel beds to be related to
both WMLs and lacunar infarcts [79]. Besides our quan-
titative measures of brain tissue atrophy and lesion volume,
DTI added new quantitative information on tissue micro-
structural integrity, as further elaborated upon below.
Finally, in collaboration with research partners in the
CHARGE consortium [80], we performed a genome-wide
association study of WML burden and were able to identify
6 novel risk-associated SNPs on chromosome 17q25 [81],
which we subsequently replicated in a separate Rotterdam
Scan Study cohort [46]. After Apolipoprotein E (APOE)
this is the ﬁrst common genetic variant to be robustly
associated with brain pathology on MRI. Similar analyses
have been undertaken for brain infarcts [82]. These are
only the ﬁrst of more projects that will combine genetic
information and imaging markers in the Rotterdam Scan
Study.
Cerebral microbleeds
In 200 Rotterdam Scan Study participants, we showed that
the 3D high-resolution T2* GRE sequence detected more
microbleeds in more persons, compared with a conven-
tional MRI sequence. When we applied this high-resolution
sequence in 1,062 participants, we found that cerebral
microbleeds were present in 1 in 5 persons over age of 60
and in over 1 in 3 in persons aged 80 years and older [66].
This prevalence is much higher than reported previously,
which in part may be explained by the use of a more
sensitive MRI sequence. We recently updated this preva-
lence estimate for a larger population (4,006 persons, mean
age 60.3 years) and found that it still holds [83]. Further-
more, we have consistently shown that risk factors for
microbleeds vary according to the location of microbleeds
in the brain. Cardiovascular risk factors and markers of
ischemic small vessel disease were related to deep or in-
fratentorial microbleeds, whilst APOE genotype related to
strictly lobar microbleeds [66, 83]. This is indirect evi-
dence that deep or infratentorial microbleeds result from
arteriolosclerotic angiopathy, whereas strictly lobar mi-
crobleeds are caused by cerebral amyloid angiopathy. This
is also corroborated by our ﬁnding that spatial distribution
of lobar microbleeds in our population follows the known
topographic distribution of amyloid angiopathy [84].
The high prevalence of cerebral microbleeds and their
potential link with bleeding-prone microangiopathy raised
our interest in how these relate to antithrombotic drug use.
We found that persons who had used or were using anti-
thrombotic medication signiﬁcantly more often had cere-
bral microbleeds [85]. Longitudinal research needs to
conﬁrm this association and may unravel a potential link
with risk of symptomatic intracerebral hemorrhage. Inter-
estingly, we found a potential link between microbleeds
and symptomatic intracerebral hemorrhage when investi-
gating lipid factions as risk factor for both [86].
We also studied the occurrence of incident microbleeds
on follow-up MR imaging after an interval of 3–4 years.
We found that 10% of persons developed new microbleeds
and that this was strongly related to presence of micro-
bleeds at baseline, but also to various risk factors such as
hypertension and smoking [87]. Again, risk factors differed
according to the location of new microbleeds, lending
further support to the hypothesis on microbleed etiology.
Finally, we recently showed that presence of numerous
microbleeds, especially in a strictly lobar location, was
associated with worse performance on cognitive tests, even
after adjustment for vascular risk factors and other imaging
markers of small vessel disease [88]. These results suggest
an independent role for microbleed-associated vasculopa-
thy in cognitive impairment.
Cerebral blood ﬂow
Total cerebral blood ﬂow (tCBF) and total brain perfusion
(tCBF per 100 ml brain tissue) were measured with 2D
phase contrast imaging as described above. We showed a
close relationship between tCBF and markers of the
microvasculature, e.g. retinal vessel diameters [77]. In 892
persons aged 60 years and older, we further showed that
determinants of tCBF and total brain perfusion differed
largely, due to the large inﬂuence of brain volume on tCBF
values [89]. Higher pulse pressure, higher body mass
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total brain perfusion. Furthermore, persons with low total
brain perfusion had signiﬁcantly more white matter lesions
compared to those with high total brain perfusion. The role
of tCBF with cognitive performance appeared more com-
plex with brain atrophy either confounding or mediating
the association [90].
White matter microstructural integrity
We have found DTI parameters within white matter lesions
and normal-appearing white matter to be associated with
cognitive function, even when taking into account volume
of white matter lesions and white matter atrophy [55]. This
indicates that the deleterious effect of white matter changes
on cognition not only depends on lesion burden or amount
of atrophy, but also on characteristics that are not easily
evaluated by conventional MRI.
Also, we demonstrated that age-related changes in the
normal-appearing white matter are primarily explained by
white matter atrophy and white matter lesion formation and
not by the aging process in itself. Furthermore, we found
that white matter atrophy and white matter lesion formation
related to loss of integrity in distinct brain regions, indi-
cating that the two processes are not sequential events but
are rather independent and thus pathophysiologically
potentially different [56].
Future perspectives
The Rotterdam Scan Study provides a unique environment
to study the etiology of neurological diseases in the elderly.
Nearly 6,000 persons have already undergone brain MRI-
scanning and in coming years repeated waves of follow-up
examination will ensure a wealth of imaging data, both
cross-sectional and longitudinal. So far, the focus of
research has been on ﬁnding risk factors and determinants
of brain pathology. In the coming years we hope to expand
the scope of research in several ways, which include novel
image sequences, novel post-processing techniques, novel
risk factors, and study the relationship of imaging markers
with clinical outcomes.
Currently, we are performing pilot studies to investigate
thefeasibilityofrestingstatefunctionalMRIintheRotterdam
Scan Study. This will allow us to explore not only structural
markers of brain pathology, but also functional correlates
thereof. The current planning is to fully incorporate BOLD-
fMRI in the core scanning protocol by the end of 2011.
In the coming years ongoing hardware developments
will necessitate upgrading of the scanner. Although there
are no current plans to change the scanner, we foresee
upgrading to a 3 Tesla scanner in a few years.
Standardized and evaluated automated image processing
techniques are crucial in exploiting the rich information
that is available in population imaging data. They have
enabled a transition from qualitative image interpretation
into quantitative imaging. Quantitative imaging is non-
trivial; it requires standardization and optimization in all
the steps from data acquisition, to data analysis in struc-
tured reporting. In the next years, the number of validated
quantitative image analysis techniques will further
increase, also including more complex measures. Also, the
results of these analyses will increasingly be stored in a
standardized manner. This will enable a richer character-
ization of brain anatomy, pathology, connectivity and
function. Relating these quantitative image measures to
disease status, progression and events, will be a powerful
tool for development of novel diagnostic and prognostic
quantitative imaging biomarkers.
The standardization of image acquisition and processing
protocols also implies that high quality reference data are
being acquired. These can be used in a clinical setting to
contrast ﬁndings in an individual with a reference
population.
Our visual ratings currently include infarcts and mi-
crobleeds. We are exploring the possibilities of developing
a validated visual rating for enlaraged Virchow Robin-
spaces (perivascular spaces). Evidence suggests that these
may be a hallmark of either small vessel disease or atrophy
[91, 92].
Finally, the concomitant continuous monitoring of all
participants in the Rotterdam Study ensure that we have a
wealth of clinical data available, including cognitive per-
formance and the occurrence of dementia and stroke. By
the end of 2012, we will already have 6 years of clinical
follow-up for the ﬁrst participants of the Rotterdam Scan
Study. In the coming years we hope to investigate how
MRI markers of brain pathology relate to these clinical
outcomes. It will be especially interesting to investigate
how the recently introduced markers, i.e. microbleeds,
microstructural integrity, and cerebral blood ﬂow, relate to
incident disease, and whether these markers can contribute
additional information on top of established markers, such
as white matter lesions and infarcts.
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